CathVision is a medical technology company founded in 2013 and headquartered in Copenhagen, Denmark, specializing in electrophysiology (EP) recording technologies and developer of the FDA-cleared ECGenius System.
Subscribe to see CathVision’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CathVision is a healthcare company headquartered in Denmark. Its most recent funding round raised $9M in July 2023. Xcout tracks 9 named people at CathVision, including Mads Emil Matthiesen (Co-Founder & CEO).
3 more named people on record for CathVision, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $9M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of CathVision's closest competitors — see the full list of competitors and alternatives →
Cortex, Inc. is a medical technology company based in Menlo Park, California. The company specializes in the medical device sector, focusing specifically on innovative products for the diagnosis and treatment of atrial arrhythmias.
CoreMap, Inc. is a medical technology company headquartered in Winooski, Vermont, developing advanced diagnostic and mapping tools to improve the treatment of atrial fibrillation.
CoraVie Medical is an early-stage medical device company headquartered in Minneapolis, Minnesota, transforming blood pressure monitoring with a breakthrough implantable solution.
Scandinavian Real Heart develops the Realheart TAH, a total artificial heart designed to save lives and improve the quality of life for patients with severe heart failure. The medical technology company primarily serves cardiac patients requiring surgical heart replacement solutions.
Acarix is a Swedish medical technology company that develops diagnostic tools for detecting coronary artery disease. Its CADScor System uses cardiac sound analysis to help clinicians assess patients with suspected coronary artery disease and determine whether further testing may be needed.
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.